RBC Capital Reiterates Sector Perform on Sage Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on Sage Therapeutics, maintaining a price target of $25.
August 08, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sage Therapeutics' stock rating has been reiterated as 'Sector Perform' by RBC Capital, with a maintained price target of $25.
The reiteration of the 'Sector Perform' rating and maintained price target by RBC Capital indicates that the analyst sees the stock performing in line with the sector average. This is neither a strong buy nor sell signal, hence the neutral score. The relevance is high as the news directly pertains to SAGE. The importance is moderate as analyst ratings can influence investor sentiment but are not the only factor. The confidence is high as the information is clear and direct.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100